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Clinical Case Report and Review
ABSTRACT
Androgen secreting adrenocortical carcinoma (ACC) is a very rare disease with a poor prognosis. Approximately 80% of 
tumors are functional, most commonly secreting glucocorticoids. We herewith report a case of a huge functional ACC 
of the right adrenal gland in a 33-year-old female who presented with complaints of hirsutism, amenorrhea and an 
abdominal lump. On abdominal examination a large lump was palpable in the right hypochondrium reaching up to the 
umbilicus. Contrast-enhance computed tomography (CECT) revealed a mass in the right suprarenal region. The tumor 
measured 29 cm × 20 cm × 12 cm and weighed 7.8 kg, the largest reported case of ACC in the world to the best of 
our knowledge. 
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INTRODUCTION
Adrenocortical carcinomas (ACC) are rare tumors 
with an incidence of 0.5-2 cases per one million 
population per year and constitute 0.05-0.2% of all 
malignancies.1 There is a bimodal age distribution with 
peaks in the first decade and in the fifth decade of life.2 
ACCs develop somewhat more common in women 
than men in most large series and measure about 10 to 
12 cm. Conventional ACCs are typically large tumors 
and, as a rule, weigh more than 100gms in adults. 
Mostly these tumors weigh around 750gms. There 
is considerable variability in the reported functional 
status of adrenocortical carcinomas. Approximately 
80% of tumors are functional, most commonly 
secreting glucocorticoids (45%), glucocorticoids and 
androgenic steroids (45%), and androgenic steroids 
alone (10%). Rarely, mineralocorticoid production 
may be present.3 Functioning ACC presents earlier 
with hormonal manifestations such as virilization, 
feminization or Cushing’s syndrome. Nonfunctioning 
tumors pose a diagnostic challenge because they 
are diagnosed incidentally due to a mass effect or 
metastatic disease.4
We report a case of the largest androgen-
producing, non-metastasizing ACC mass till date. The 
patient underwent right radical nephrectomy with 
in toto excision of the tumor. On gross examination 
the tumor measured 29×20×12 cm. On microscopy 
and by immunohistochemistry (IHC) a diagnosis of 
ACC was confirmed. After performing an extensive 
google search of all the articles published on ACCs, 
to date, we report this case as the largest ACC in 
size in the world.
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CASE REPORT
A 33-year-old female presented with cessation of 
menses along with hair growth on face and body over 
the last 2 years. There was no history of hypertension, 
diabetes, tuberculosis or any other chronic disorder. 
She was on oral contraceptive pills for 5 months and 
had a 5-year-old child at the time of the first hospital 
visit. On examination, an abdominal lump was found in 
the right hypochondrium reaching up to the umbilicus 
and midline measuring ~ 20×20×15 cm. It was soft 
in consistency, non-tender with no ascites. There 
was no audible bruit or any other palpable lump. Her 
average blood pressure was 130/80 mmHg on 24-hour 
ambulatory blood pressure monitoring. Laboratory 
investigations revealed raised serum cortisol~ 22.53 
µg/dl (Reference range [RR]; 4.30-22.40µg/dl) and 
serum total testosterone~337.76 ng/dl (RR; 14-76ng/
dl). Blood sugar levels, renal function tests, liver 
function tests, serum electrolytes, hormone profile 
including serum aldosterone, and 24-hour urine 
metanephrines levels were within normal limits. A 
triphasic abdominal and pelvic contrast-enhanced 
computed tomography (CECT) demonstrated a large 
solid hypodense mass measuring 24×20×16 cm, with 
areas of necrosis and increased arterial blood supply 
(mostly direct branches of aorta) in the right adrenal 
topography. The right adrenal was not seen separately. 
The mass had displaced the portal veins, pancreas, 
inferior vena cava to the left side, and compressed the 
right kidney (Figure 1A-B).
Positron emission tomography-computed 
tomography (PET/CT) was performed for metastatic 
workup showed a large FDG avid heterogeneously 
enhancing lobulated soft tissue density mass lesion in 
the right suprarenal region (Figure 2A-B). Right adrenal 
gland was not separately visualized and no other 
abnormal hypermetabolic focus was seen elsewhere 
in the body. 
Tumor markers CA 15.3, CA125, CA 19.9 and 
AFP were not elevated. An image-guided biopsy 
was performed in some other institute where it was 
reported as consistent with an epithelial neoplasm 
with oncocytic, clear phenotype, and angular nesting 
growth pattern. Tumor cells were positive for Melan A, 
Calretinin and Vimentin suggesting an adrenal origin. 
The Ki 67 was 5-6%. The patient underwent radical 
nephrectomy with in toto excision of the tumor. Per 
operatively a large adrenal mass (right) reaching up 
to the pelvis crossing midline, and touching but not 
invading the lower border of liver and inferior vena 
cava and encroaching right kidney was found and sent 
for histopathological examination.
Figure 1. A and B – CECT showing a large solid hypodense lesion measuring 24×20×16 cm, in the right adrenal 
area displacing the portal vein, pancreas and IVC to the left side (red arrow). Mass is also compressing right kidney 
(yellow arrow).
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Grossly the large adrenal mass with the intact 
capsule measured 29×20×12 cm and weighed 7.8kg 
(Figure 3A). The cut surface showed a variegated 
appearance with large areas of necrosis(Figure 3B). 
The kidney measured 12×7×3 cm, and its cut section 
showed normal renal parenchyma with maintained 
cortico-medullary junction.
Microscopic sections from the adrenal mass 
showed a highly cellular tumor composed of cells 
arranged in sheets and nests having markedly 
pleomorphic round to oval nuclei, coarse granular 
chromatin, prominent nucleoli and moderate amount 
of eosinophilic to clear cytoplasm. Many bizarre cells 
and brisk mitotic activity was noted along with large 
areas of necrosis (Figure 4). Capsular and vascular 
invasion were not seen. Sections from periadrenal 
fat, renal cortex, medulla and hilum were free from 
tumor.
Figure 2. A and B – PET-CT showing large FDG avid heterogeneously enhancing lobulated soft tissue density mass 
lesion in the right suprarenal region. Right adrenal gland was not separately visualized.
Figure 3. A and B – Gross of giant adrenal mass measuring 29×20×12 cm with cut surface showing a variegated 
appearance and large areas of necrosis. (Scale bar = 10 cm)
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On the immunohistochemical (IHC) study, the 
tumor cells were strongly positive for Melan A and 
Vimentin (Figure 5A-B). Inhibin was weak focal positive 
(Figure 5C). The tumor was negative for Chromogranin, 
Synaptophysin, EMA, CK7 and CK20.
A final diagnosis of adrenocortical carcinoma, 
modified Weiss score 4, pathological stage T2N0M0, 
Stage II was made. Therefore, the patient was advised 
6 monthly follow up PET scans with no adjuvant 
chemotherapy. On two year follow up the patient 
had no recurrence and is doing well with a normal 
hormonal status.
DISCUSSION
Primary adrenocortical tumors are large tumors 
usually measuring more than 5 cm at presentation. 
The larger the tumor, the greater is the chance of 
being malignant. The present case was malignant and 
measured 29×20×12 cm. Didolkar et al.5 have studied 
the natural history of a large series of patients with 
adrenocortical carcinoma in which the mean duration 
of symptoms in patients with or without hormonal 
manifestations was 6 months. Fifty-two percent of 
patients had distant metastases at the time of diagnosis, 
41% had locally advanced disease, and 7% had tumor 
confined to the adrenal gland. In our case the patient 
was symptomatic for 2 years; however, the tumor 
was confined to the adrenal at the time of diagnosis. 
The overall median survival was 14 months, and the 
5-year survival rate was 24%.5 The median survival of 
patients with functional tumors was somewhat longer 
than that of patients with nonfunctional tumors. Our 
case was of a functional tumor with the patient doing 
well after two years of surgery.
The most common sites of metastasis are the 
lungs, followed by retroperitoneal lymph nodes, liver, 
and bone. Because they are large, the organ of origin 
is often difficult to determine. Therefore, the diagnosis 
on biopsy is difficult based on morphology alone and 
a panel of immunohistochemistry is required to rule 
out other differentials. In these instances, a battery of 
Figure 4. Photomicrograph showing highly cellular tumor composed of cells having markedly pleomorphic round to 
oval nuclei, coarse granular chromatin, prominent nucleoli and moderate amount of eosinophilic to clear cytoplasm. 
Many bizarre cells and brisk mitotic activity is also present (H&E; 40x).
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immunostains can provide evidence of adrenocortical 
differentiation which include α-inhibin, calretinin, 
vimentin, synaptophysin, Melan A and steroidogenic 
factor 1 (SF1). Metastasis to the adrenal is the other 
possibility. The most common tumors metastasizing to 
the adrenals are lung carcinoma, renal cell carcinoma, 
breast carcinoma, and melanoma. However, in the 
setting of metastatic carcinoma, bilateral adrenal 
masses are more likely.6 However, in surgical specimens 
a thorough examination of the tumor capsule, looking 
for capsular and vascular invasion accompanied by 
an extensive sampling of the tumor, to ensure that a 
high-grade component is not missed, should be done. 
The main differential diagnoses are adrenocortical 
adenoma, pheochromocytoma, renal cell carcinoma 
and hepatocellular carcinoma.
After extensive review of literature, we report 
a case of the largest adrenocortical carcinoma. A 
brief review of the largest reported cases has been 
depicted in Table 1. Other cases reported were all 
less than 20 cm in size.4-10 The initial classification 
of ACC took into account the size of the tumor as 
determinant to the diagnosis of malignant behavior. 
However, currently, along with tumor size, histologic 
criteria evolved to incorporate a variety of histological, 
and immunohistochemical parameters. The Weiss 
system11 and its modifications have gained the most 
acceptance in clinical practice as the diagnostic criteria 
for ACC. Modified Weiss criteria include the following 
criteria: (i) mitotic rate > 5 per 50 high power fields, 
(ii) cytoplasm (clear cells comprising 25% or less of 
the tumor), (iii) abnormal mitoses, (iv) necrosis and (v) 
capsular invasion. To calculate each criterion is scored 
0 when absent and 1 when present: 2x mitotic rate 
criterion + 2x clear cytoplasm criterion + abnormal 
mitoses + necrosis + capsular invasion (score of 3 or 
more suggests malignancy). The modified Weiss score 
of our case was 4.
Figure 5. A and B – Tumor cells showing strong cytoplasmic positivity for Melan A & Vimentin (Figure 5A-B); 
C – Focal weak positivity for Inhibin (IHC; 40x) (Figure 5C).
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Currently, complete tumor resection is the only 
curative approach to ACC. Adjuvant chemotherapy 
has a role in decreasing the chance of recurrence and 
increase survival.12 Also large tumor size (diameter > 
12 cm) has been associated with poor survival after 
complete resection.2 Although our case is the largest 
case of ACC , the patient is doing well at 2 year follow 
up. Postoperative surveillance should be performed at 
every 3 months for the first 2 years and then every six 
months for 5 years to look for recurrence or metastasis 
by FDG-PET/CT scan. The prognosis is highly stage-
dependent and over the years several staging systems 
have been proposed. Currently, the ENSAT (European 
Network for the Study of Adrenal Tumors) classification 
is commonly used. Five-year survival for patients with 
disease confined to adrenal gland is size-dependent, 
varies from 61% to 82%; those with distant metastasis 
at diagnosis have a five-year survival of only 18%.13
CONCLUSION
ACC is a rare malignancy with a size dependent 
prognosis. This case has been reported because of 
the gigantic size yet non metastasizing nature of the 
tumor. The case was managed by complete surgical 
removal and had an excellent prognosis despite the 
large size, as the tumor did not invade the nearby 
organs and was removed in toto. To the best of our 
knowledge, this is the largest ACC reported till date.
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Kunieda et al.7 52Y/M Weight loss & Abdominal discomfort
Functional 
ACC 29×19×10 4700
Tumor extirpation with 
partial liver resection
Straka et al.8 40Y/M Respiratory distress Functional ACC 26×16×13 2372 In toto excision of tumor
Uruc et al.9 48Y/F Abdominal pain & Flushing
Functional 
ACC 23×18×16 1300 En bloc removal of tumor
Present case 33Y/F Amenorrhea & Hirsutism
Functional 
ACC 29×20×12 7800
In toto excision of tumor 
with radical nephrectomy
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